PL358482A1 - Związki do ukierunkowanego wprowadzania - Google Patents

Związki do ukierunkowanego wprowadzania

Info

Publication number
PL358482A1
PL358482A1 PL01358482A PL35848201A PL358482A1 PL 358482 A1 PL358482 A1 PL 358482A1 PL 01358482 A PL01358482 A PL 01358482A PL 35848201 A PL35848201 A PL 35848201A PL 358482 A1 PL358482 A1 PL 358482A1
Authority
PL
Poland
Prior art keywords
caspase
compound
compounds
cytotoxic
constitutively active
Prior art date
Application number
PL01358482A
Other languages
English (en)
Inventor
Agamemnon Antoniou Epenetos
Original Assignee
Antisoma Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antisoma Research Limited filed Critical Antisoma Research Limited
Publication of PL358482A1 publication Critical patent/PL358482A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22056—Caspase-3 (3.4.22.56)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22059—Caspase-6 (3.4.22.59)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL01358482A 2000-03-28 2001-03-28 Związki do ukierunkowanego wprowadzania PL358482A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0007343A GB2360771A (en) 2000-03-28 2000-03-28 Compounds for targeting
PCT/GB2001/001354 WO2001072336A1 (en) 2000-03-28 2001-03-28 Compounds for targeting

Publications (1)

Publication Number Publication Date
PL358482A1 true PL358482A1 (pl) 2004-08-09

Family

ID=9888460

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01358482A PL358482A1 (pl) 2000-03-28 2001-03-28 Związki do ukierunkowanego wprowadzania

Country Status (21)

Country Link
EP (1) EP1267940B1 (pl)
JP (1) JP2003528156A (pl)
KR (1) KR20030022782A (pl)
CN (1) CN1420789A (pl)
AT (1) ATE240122T1 (pl)
AU (1) AU4850101A (pl)
BR (1) BR0109570A (pl)
CA (1) CA2402453A1 (pl)
DE (1) DE60100274T2 (pl)
DK (1) DK1267940T3 (pl)
ES (1) ES2202287T3 (pl)
GB (2) GB2360771A (pl)
IL (1) IL151675A0 (pl)
MX (1) MXPA02009376A (pl)
NO (1) NO20024587L (pl)
NZ (1) NZ521289A (pl)
PL (1) PL358482A1 (pl)
PT (1) PT1267940E (pl)
RU (1) RU2002128746A (pl)
WO (1) WO2001072336A1 (pl)
ZA (1) ZA200207157B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU783679B2 (en) * 2000-02-24 2005-11-24 Genentech Inc. Caspase activated prodrugs therapy
CA2475247C (en) * 2002-02-07 2015-08-04 Massachusetts Institute Of Technology Anti-pathogen treatments
EP2571992B1 (en) * 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
JP7592621B2 (ja) * 2019-04-02 2024-12-02 イミュネチューン・ベー・フェー 免疫刺激組成物及びその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
DE69133036T2 (de) * 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
WO1994011508A2 (en) * 1992-11-13 1994-05-26 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
GB2289679B (en) * 1993-01-15 1997-02-05 Imp Cancer Res Tech Compounds comprising a target cell-specific portion and a portion which has DNA endonucleolytic activity, and uses thereof
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6379950B1 (en) * 1998-01-09 2002-04-30 Thomas Jefferson University Recombinant, active caspases and uses thereof
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities

Also Published As

Publication number Publication date
GB2360771A (en) 2001-10-03
CA2402453A1 (en) 2001-10-04
MXPA02009376A (es) 2004-05-14
DE60100274T2 (de) 2004-04-01
GB0107725D0 (en) 2001-05-16
GB2360772A (en) 2001-10-03
IL151675A0 (en) 2003-04-10
ZA200207157B (en) 2003-12-05
BR0109570A (pt) 2003-01-28
DE60100274D1 (de) 2003-06-18
NO20024587L (no) 2002-11-25
KR20030022782A (ko) 2003-03-17
NZ521289A (en) 2004-04-30
EP1267940B1 (en) 2003-05-14
ATE240122T1 (de) 2003-05-15
PT1267940E (pt) 2003-09-30
ES2202287T3 (es) 2004-04-01
NO20024587D0 (no) 2002-09-25
EP1267940A1 (en) 2003-01-02
DK1267940T3 (da) 2003-09-08
GB0007343D0 (en) 2000-05-17
CN1420789A (zh) 2003-05-28
AU4850101A (en) 2001-10-08
GB2360772B (en) 2002-05-22
RU2002128746A (ru) 2004-03-27
JP2003528156A (ja) 2003-09-24
WO2001072336A1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
BR0308090A (pt) conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
DE60033649D1 (de) Verbindungen und therapeutische methoden
IL115517A0 (en) Biologically active proteins
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2001087227A3 (en) Drug containing polymeric micelles
NO20055838L (no) Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav
HUP9802961A2 (hu) Kötési partner ciklinfüggő kinázok inhibitoraihoz és ezek alkalmazása inhibitorok kereséséhez, valamint egy betegség diagnózisához vagy terápiájához
NO20055209D0 (no) Peptabody for cancerbehandling
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
PL358482A1 (pl) Związki do ukierunkowanego wprowadzania
PT1435991E (pt) Utilização de aplidina para o tratamento de cancro pancreático
AU2001233917A1 (en) Bcmp-7 as marker for diagnosis of breast cancer
ATE314856T1 (de) Ribozym-therapie zur behandlung von proliferativen augenkranheiten
ATE407702T1 (de) Liposomale einkapselung von alphastrahlern, und deren verwendung
DK1602669T3 (da) Antistof mod et tumor-specifikt antigen som target
FR2813606B1 (fr) Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques
ATE477324T1 (de) Dna-enzym zur hemmung von plasminogenaktivator- inhibitor-1
AU2990300A (en) Deglycosylated kringle 1-5 region fragments of plasminogen and methods of use
PT980379E (pt) Oligonucleotidos quimericos e sua utilizacao
UA34406A (uk) Засіб для лікування розсіяного склерозу, спосіб лікування з його використанням та фармацевтична упаковка
MXPA04003673A (es) Uso de aplidina para el tratamiento de cancer pancreatico.
ATE490981T1 (de) Criptospezifische antikörper
WO2002095062A3 (en) Serine-threonine phosphatase protein of a parasitic organism of the apicomplexa phylum, applications in therapeutics

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)